Elevated cutaneous smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5101-5107

  Harradine, Kelly A ^a,b   Ridd, Katie ^a,b   Saunier, Elise F ^a,b   Clermont, Frederic F ^a,b   Perez Losada, Jesus ^a,b,c   Moore, Dan H ^a,b   Epstein Jr , Ervin H ^a,b,d   Bastian, Boris C ^a,b   Akhurst, Rosemary J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIREJECTION AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CANCER TISSUE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN CANCER; SKIN CARCINOMA; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

AGE FACTORS; BONE MORPHOGENETIC PROTEINS; CARCINOMA, SQUAMOUS CELL; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; SMAD PROTEINS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTS; UP-REGULATION;

EID: 69349103707     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3286     Document Type: Article

References (50)

1. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-1667
2. Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007;8: 921-932 (Pubitemid 47488067)
3. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003;49:397-406. (Pubitemid 37051900)
4. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27: 1767-1768
5. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998;30:1124-1126 (Pubitemid 28309508)
6. Bavinck JN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993; 129:242-249 (Pubitemid 23283993)
7. Harwood CA, Surentheran T, Sasieni P, et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004;150:949-957 (Pubitemid 38903528)
8. Busnach G, Piselli P, Arbustini E, et al. Immuno-suppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006;38:3533-3535 (Pubitemid 44908520)
9. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831
10. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907 (Pubitemid 350231320)
11. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135 (Pubitemid 34155123)
12. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73: 1565-1572 (Pubitemid 34568667)
13. Law BK, Chytil A, Dumont N, et al. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002;22:8184-8198 (Pubitemid 35304052)
14. Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008;128:2467-2473
15. Tanaka T, Takahara S, Hatori M, et al. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 2002;181:165-171 (Pubitemid 34518300)
16. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-534 (Pubitemid 29093252)
17. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. Transplantation 2003;76:597-602. (Pubitemid 37013269)
18. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129 (Pubitemid 32952643)
19. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-584 (Pubitemid 37280136)
20. Flanders KC, Thompson NL, Cissel DS, et al. Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J Cell Biol 1989;108:653-660
21. Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8: 970-982 (Pubitemid 350174642)
22. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Ultraviolet irradiation alters transforming growth factor β/smad pathway in human skin in vivo. J Invest Dermatol 2002;119:499-506. (Pubitemid 35001963)
23. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Solar ultraviolet irradiation reduces collagen in photoaged human skin by blocking transforming growth factor-β type II receptor/Smad signaling. Am J Pathol 2004;165:741-751 (Pubitemid 39129282)
24. Han KH, Choi HR, Won CH, et al. Alteration of the TGF-β/SMAD pathway in intrinsically and UV-induced skin aging. Mech Ageing Dev 2005; 126:560-567
25. Coupes BM, Newstead CG, Short CD, Brenchley PE. Transforming growth factor β1 in renal allograft recipients. Transplantation 1994;57: 1727-1731 (Pubitemid 24206411)
26. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-β1 in humans: stimulation by cyclosporine. Transplantation 1998;65:313-318
27. Citterio F, Pozzetto U, Romagnoli J, et al. Plasma levels of transforming growth factor-β1 in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc 2004;36:698-699 (Pubitemid 38534364)
28. Cui W, Fowlis DJ, Bryson S, et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-542 (Pubitemid 26299485)
29. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-494 (Pubitemid 34752433)
30. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;64:4405-4410 (Pubitemid 38856909)
31. Ohsawa I, Murakami T, Uemoto S, Kobayashi E. In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Transplantation 2006;81:1558-1567
32. Han G, Lu SL, Li AG, et al. Distinct mechanisms of TGF-β1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest 2005;115:1714-1723 (Pubitemid 40979710)
33. Hoot KE, Lighthall J, Han G, et al. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest 2008;118:2722-2732
34. Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E. Loss of TGFβ signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 2007;12:313-327 (Pubitemid 47539305)
35. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 2004; 110:3822-3829 (Pubitemid 40023981)
36. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor β1 has a longer plasma half-life in rats than active transforming growth factor β1, and a different tissue distribution. J Clin Invest 1990;86: 1976-1984
37. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 2003;5:410-421 (Pubitemid 36592263)
38. Harradine KA, Akhurst RJ. Mutations of TGFβ signaling molecules in human disease. Ann Med 2006;38:403-414 (Pubitemid 44484878)
39. Massague J. Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 2003;17:2993-2997 (Pubitemid 38040762)
40. Sekimoto G, Matsuzaki K, Yoshida K, et al. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 2007;67:5090-5096 (Pubitemid 46997243)
41. Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-β1 in mice: stimulation by cyclosporine. Transplantation 1997;63: 1037-1039
42. Fisher BK, Elliott GB. On the origin of keratoacanthoma: reflections on an unusual lesion. Can Med Assoc J 1965;93:272-273
43. Zhang J, He XC, Tong WG, et al. Bone morphogenetic protein signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion. Stem Cells 2006;24:2826-2839 (Pubitemid 46053019)
44. Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 2008;132: 299-310. (Pubitemid 351172432)
45. Plikus MV, Mayer JA, de la Cruz D, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature 2008; 451:340-344
46. Kobielak K, Pasolli HA, Alonso L, Polak L, Fuchs E. Defining BMP functions in the hair follicle by conditional ablation of BMP receptor IA. J Cell Biol 2003;163:609-623 (Pubitemid 37429873)
47. Saunier EF, Akhurst RJ. TGF β inhibition for cancer therapy. Curr Cancer Drug Targets 2006; 6:565-578
48. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719 (Pubitemid 29353172)
49. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121
50. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450-455